Duncan McCloskey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Duncan McCloskey has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- David Erickson
Cornell University
5 shared publications Juan Boza
Meinig School of Biomedical Engineering, Cornell University, Ithaca, NY 14850, USA
2 shared publicationsAggrey Semeere
Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda
1 shared publication- Andrea L. Gardner
Department of Biomedical Engineering, The University of Texas at Austin
1 shared publication Ankur Singh
Sibley School of Mechanical and Aerospace Engineering, Cornell University, Ithaca, USA
1 shared publicationAntonella Schiavinato
Fidia Farmaceutici S.p.A, Abano Terme, PD 35031, Italy
1 shared publication
Latest Publications
- Open Access
- 22 June 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (7) , e70640
A Phase 1, Open‐Label, Randomized Study to Investigate the Pharmacokinetics and Safety of Multiple Doses of Intranasal Naloxone in Healthy Participants
This was a Phase 1, open label, randomized, crossover study to evaluate the safety and pharmacokinetics of multiple doses of intranasal naloxone (NCT05377255). Twenty‐four healthy participants were enrolled at a single site in the US to one of two sequences. Participants received four doses of 4 mg intranasal (IN) naloxone using two two‐dose devices (AP003; single dose at 0, 2.5, 5.0, and 7.5 min) or two doses of 4 mg naloxone using two one‐dose devices (single dose at 0 and 2.5 min). Treatments were separated by a 48‐h washout, the order being driven by the crossover sequence. Blood samples were collected predose and at defined timepoints post‐dosing for analysis of free and total naloxone, which were used for the noncompartmental PK analysis. Safety was assessed through physical exams, vital signs, electrocardiograms, continuous cardiac monitoring, clinical labs, olfactory assessments, rhinoscopy, and treatment emergent adverse events. Of the 24 participants, most were Female ( n = 14, 58.3%), White ( n = 20, 83.3%), and Hispanic or Latino ( n = 24, 100%), with a mean age of 38.1 years and baseline body mass index of 26.2 kg/m 2 . Naloxone concentrations increased similarly over 15 min and doubled for the AP003 group at 20 min, thereby meeting the primary objective. There was a dose‐dependent increase in C max , AUC 0‐inf , pAUC, and AUC 0‐ t ; however, statistical significance for dose proportionality was not seen in AUC 0‐inf , AUC 0‐ t , and C max . All treatment emergent adverse events were mild or moderate in severity and no serious adverse events were reported.
- 22 June 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (7) , e70640
Open AccessA Phase 1, Open‐Label, Randomized Study to Investigate the Pharmacokinetics and Safety of Multiple Doses of Intranasal Naloxone in Healthy Participants
This was a Phase 1, open label, randomized, crossover study to evaluate the safety and pharmacokinetics of multiple doses of intranasal naloxone (NCT05377255). Twenty‐four healthy participants were enrolled at a single site in the US to one of two sequences. Participants received four doses of 4 mg intranasal (IN) naloxone using two two‐dose devices (AP003; single dose at 0, 2.5, 5.0, and 7.5 min) or two doses of 4 mg naloxone using two one‐dose devices (single dose at 0 and 2.5 min). Treatments were separated by a 48‐h washout, the order being driven by the crossover sequence. Blood samples were collected predose and at defined timepoints post‐dosing for analysis of free and total naloxone, which were used for the noncompartmental PK analysis. Safety was assessed through physical exams, vital signs, electrocardiograms, continuous cardiac monitoring, clinical labs, olfactory assessments, rhinoscopy, and treatment emergent adverse events. Of the 24 participants, most were Female ( n = 14, 58.3%), White ( n = 20, 83.3%), and Hispanic or Latino ( n = 24, 100%), with a mean age of 38.1 years and baseline body mass index of 26.2 kg/m 2 . Naloxone concentrations increased similarly over 15 min and doubled for the AP003 group at 20 min, thereby meeting the primary objective. There was a dose‐dependent increase in C max , AUC 0‐inf , pAUC, and AUC 0‐ t ; however, statistical significance for dose proportionality was not seen in AUC 0‐inf , AUC 0‐ t , and C max . All treatment emergent adverse events were mild or moderate in severity and no serious adverse events were reported.
- Open Access
- 13 January 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (2) , eadc8913
LAMP-enabled diagnosis of Kaposi’s sarcoma for sub-Saharan Africa
Kaposi’s sarcoma (KS) is an endothelial cancer caused by the Kaposi’s sarcoma-associated herpesvirus (KSHV) and is one of the most common cancers in sub-Saharan Africa. In limited-resource settings, traditional pathology infrastructure is often insufficient for timely diagnosis, leading to frequent diagnoses at advanced-stage disease where survival is poor. In this study, we investigate molecular diagnosis of KS performed in a point-of-care device to circumvent the limited infrastructure for traditional diagnosis. Using 506 mucocutaneous biopsies collected from patients at three HIV clinics in Uganda, we achieved 97% sensitivity, 92% specificity, and 96% accuracy compared to gold standard U.S.-based pathology. The results presented in this manuscript show that LAMP-based quantification of KSHV DNA extracted from KS-suspected biopsies has the potential to serve as a successful diagnostic for the disease and that diagnosis may be accurately achieved using a point-of-care device, reducing the barriers to obtaining KS diagnosis while increasing diagnostic accuracy.
- 13 January 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (2) , eadc8913
Open AccessLAMP-enabled diagnosis of Kaposi’s sarcoma for sub-Saharan Africa
Kaposi’s sarcoma (KS) is an endothelial cancer caused by the Kaposi’s sarcoma-associated herpesvirus (KSHV) and is one of the most common cancers in sub-Saharan Africa. In limited-resource settings, traditional pathology infrastructure is often insufficient for timely diagnosis, leading to frequent diagnoses at advanced-stage disease where survival is poor. In this study, we investigate molecular diagnosis of KS performed in a point-of-care device to circumvent the limited infrastructure for traditional diagnosis. Using 506 mucocutaneous biopsies collected from patients at three HIV clinics in Uganda, we achieved 97% sensitivity, 92% specificity, and 96% accuracy compared to gold standard U.S.-based pathology. The results presented in this manuscript show that LAMP-based quantification of KSHV DNA extracted from KS-suspected biopsies has the potential to serve as a successful diagnostic for the disease and that diagnosis may be accurately achieved using a point-of-care device, reducing the barriers to obtaining KS diagnosis while increasing diagnostic accuracy.
- 24 August 2022
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 216, 114654
MINI: A high-throughput point-of-care device for performing hundreds of nucleic acid tests per day
- 24 August 2022
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 216, 114654
MINI: A high-throughput point-of-care device for performing hundreds of nucleic acid tests per day
- 13 July 2022
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 22 (17) , 3229-3235
Rapid nucleic acid extraction from skin biopsies using a point-of-care device
BLENDER is a point-of-care device for rapid sample processing of large, robust tissue such as skin punch biopsies.
- 13 July 2022
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 22 (17) , 3229-3235
Rapid nucleic acid extraction from skin biopsies using a point-of-care device
BLENDER is a point-of-care device for rapid sample processing of large, robust tissue such as skin punch biopsies.
- Top Cited Papers
- 11 March 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 12 (534)
Combined nucleus pulposus augmentation and annulus fibrosus repair prevents acute intervertebral disc degeneration after discectomy
Tissue-engineered therapies targeting the nucleus pulposus and annulus fibrosus prevent intervertebral disc degeneration after discectomy in sheep.
- 11 March 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 12 (534)
Top Cited PapersCombined nucleus pulposus augmentation and annulus fibrosus repair prevents acute intervertebral disc degeneration after discectomy
Tissue-engineered therapies targeting the nucleus pulposus and annulus fibrosus prevent intervertebral disc degeneration after discectomy in sheep.
- Open Access
- 17 February 2020
- Published by IOP Publishing in Smart Materials and Structures
- Vol. 29 (4) , 045038
An energy-flexible mechanism for qPCR thermal cycling using shape memory alloys
We present a mechanism for thermal cycling that does not require electricity; instead, the device functions as a heat engine and requires only a generic heat source and a shape memory alloy (SMA) spring. The SMA spring mechanically translates to a low-temperature reservoir when heated, and the subsequent cooling of the spring causes translation back to a high-temperature reservoir. The usefulness of the mechanism is displayed by performing the quantitative polymerase chain reaction (qPCR), an important biological assay that requires thermal cycling for amplification of nucleic acids. The ability to perform qPCR with a generic heat source enables a variety of significant health diagnostic tests to be performed in resource limited settings, where electricity access may not be available or reliable. We demonstrate robust thermal cycling using a direct flame, sunlight, and electricity as heat sources, with maximum heating and cooling rates of 4.4 °C s−1 and −2.7 °C s−1, respectively.
- 17 February 2020
- Published by IOP Publishing in Smart Materials and Structures
- Vol. 29 (4) , 045038
Open AccessAn energy-flexible mechanism for qPCR thermal cycling using shape memory alloys
We present a mechanism for thermal cycling that does not require electricity; instead, the device functions as a heat engine and requires only a generic heat source and a shape memory alloy (SMA) spring. The SMA spring mechanically translates to a low-temperature reservoir when heated, and the subsequent cooling of the spring causes translation back to a high-temperature reservoir. The usefulness of the mechanism is displayed by performing the quantitative polymerase chain reaction (qPCR), an important biological assay that requires thermal cycling for amplification of nucleic acids. The ability to perform qPCR with a generic heat source enables a variety of significant health diagnostic tests to be performed in resource limited settings, where electricity access may not be available or reliable. We demonstrate robust thermal cycling using a direct flame, sunlight, and electricity as heat sources, with maximum heating and cooling rates of 4.4 °C s−1 and −2.7 °C s−1, respectively.
- 6 February 2019
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 19 (5) , 728-737
Point of care technologies for sepsis diagnosis and treatment
Development of new point of care tools for sepsis has the potential to improve diagnostic speed and accuracy, leading to prompt administration of appropriate therapeutics, thereby reducing healthcare costs and improving patient outcomes.
- 6 February 2019
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 19 (5) , 728-737
Point of care technologies for sepsis diagnosis and treatment
Development of new point of care tools for sepsis has the potential to improve diagnostic speed and accuracy, leading to prompt administration of appropriate therapeutics, thereby reducing healthcare costs and improving patient outcomes.